USD 28.21
(-7.48%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 | 59.8 Thousand USD | -81.51% |
2023 | 463.66 Thousand USD | -39.88% |
2022 | 771.25 Thousand USD | -79.05% |
2021 | 3.68 Million USD | 19.94% |
2020 | 3.06 Million USD | 47.46% |
2019 | 2.08 Million USD | -99.91% |
2018 | 2.36 Billion USD | 6.45% |
2017 | 2.22 Billion USD | -1.47% |
2016 | 2.25 Billion USD | -0.43% |
2015 | 2.26 Billion USD | 0.0% |
2013 | 2.21 Billion USD | 14.64% |
2012 | 1.93 Billion USD | -2.96% |
2011 | 1.99 Billion USD | 4.39% |
2010 | 1.9 Billion USD | 1140.06% |
2009 | 154 Million USD | 0.0% |
2007 | 1.86 Billion USD | -0.9% |
2006 | 1.88 Billion USD | -0.53% |
2005 | 1.89 Billion USD | 75.58% |
2004 | 1.07 Billion USD | 0.0% |
2002 | 561 Million USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | - USD | -100.0% |
2024 Q2 | - USD | 0.0% |
2024 Q4 | 59.8 Thousand USD | 0.0% |
2023 Q1 | - USD | -100.0% |
2023 Q2 | - USD | 0.0% |
2023 Q4 | 463.66 Thousand USD | 1725.04% |
2023 FY | 463.66 Thousand USD | -39.88% |
2023 Q3 | 25.4 Thousand USD | 0.0% |
2022 Q4 | 771.25 Thousand USD | 114.08% |
2022 FY | 771.25 Thousand USD | -79.05% |
2022 Q3 | 360.26 Thousand USD | 26316.1% |
2022 Q1 | 1.36 Million USD | -62.96% |
2022 Q2 | 1363.82 USD | -99.9% |
2021 Q1 | 3.54 Million USD | 15.41% |
2021 FY | 3.68 Million USD | 19.94% |
2021 Q4 | 3.68 Million USD | 0.0% |
2021 Q2 | 3.54 Million USD | 0.0% |
2021 Q3 | 3.68 Million USD | 3.92% |
2020 Q3 | 3.06 Million USD | 0.0% |
2020 Q1 | - USD | 0.0% |
2020 FY | 3.06 Million USD | 47.46% |
2020 Q4 | 3.06 Million USD | 0.0% |
2019 FY | 2.08 Million USD | -99.91% |
2018 Q1 | 2.36 Billion USD | -0.06% |
2018 Q2 | 2.36 Billion USD | -0.12% |
2018 FY | 2.36 Billion USD | 6.45% |
2017 Q4 | 2.37 Billion USD | 6.71% |
2017 Q1 | 2.22 Billion USD | -0.09% |
2017 Q2 | 2.22 Billion USD | 0.04% |
2017 Q3 | 2.22 Billion USD | -0.06% |
2017 FY | 2.22 Billion USD | -1.47% |
2016 Q1 | 2.25 Billion USD | -0.14% |
2016 FY | 2.25 Billion USD | -0.43% |
2016 Q4 | 2.22 Billion USD | 0.08% |
2016 Q3 | 2.22 Billion USD | -1.49% |
2016 Q2 | 2.25 Billion USD | -0.15% |
2015 FY | 2.26 Billion USD | 0.0% |
2015 Q1 | 2.27 Billion USD | -0.17% |
2015 Q4 | 2.26 Billion USD | 0.01% |
2015 Q3 | 2.26 Billion USD | -0.16% |
2015 Q2 | 2.26 Billion USD | -0.29% |
2014 Q2 | 2.21 Billion USD | 0.28% |
2014 Q4 | 2.27 Billion USD | -5.66% |
2014 Q3 | 2.41 Billion USD | 8.79% |
2014 Q1 | 2.21 Billion USD | -0.14% |
2013 FY | 2.21 Billion USD | 14.64% |
2013 Q4 | 2.21 Billion USD | 1.66% |
2013 Q2 | 1.93 Billion USD | -0.13% |
2013 Q3 | 2.17 Billion USD | 12.6% |
2013 Q1 | 1.93 Billion USD | -0.16% |
2012 Q2 | 1.94 Billion USD | -0.13% |
2012 FY | 1.93 Billion USD | -2.96% |
2012 Q4 | 1.94 Billion USD | -0.12% |
2012 Q3 | 1.94 Billion USD | -0.16% |
2012 Q1 | 1.94 Billion USD | -0.03% |
2011 Q2 | 1.99 Billion USD | -3.85% |
2011 Q1 | 2.07 Billion USD | 9.47% |
2011 Q3 | 1.95 Billion USD | -2.14% |
2011 FY | 1.99 Billion USD | 4.39% |
2011 Q4 | 1.94 Billion USD | -0.12% |
2010 Q1 | 131 Million USD | -13.82% |
2010 Q3 | 128 Million USD | -93.3% |
2010 Q4 | 1.89 Billion USD | 1379.61% |
2010 Q2 | 1.9 Billion USD | 1357.79% |
2010 FY | 1.9 Billion USD | 1140.06% |
2009 FY | 154 Million USD | 0.0% |
2009 Q1 | 1.92 Billion USD | -0.21% |
2009 Q2 | 154 Million USD | -92.01% |
2009 Q3 | 134 Million USD | -12.99% |
2009 Q4 | 152 Million USD | 13.43% |
2008 Q4 | 1.93 Billion USD | -1.88% |
2008 Q2 | 1.86 Billion USD | -0.21% |
2008 Q3 | 1.96 Billion USD | 5.63% |
2008 Q1 | 1.86 Billion USD | -0.21% |
2007 Q4 | 1.87 Billion USD | -0.27% |
2007 FY | 1.86 Billion USD | -0.9% |
2007 Q3 | 1.87 Billion USD | -0.21% |
2007 Q2 | 1.88 Billion USD | 1.73% |
2007 Q1 | 1.84 Billion USD | -0.59% |
2006 Q4 | 1.86 Billion USD | -0.27% |
2006 Q3 | 1.86 Billion USD | -0.37% |
2006 Q2 | 1.87 Billion USD | -0.21% |
2006 Q1 | 1.87 Billion USD | -4.71% |
2006 FY | 1.88 Billion USD | -0.53% |
2005 Q2 | 1.89 Billion USD | -4.63% |
2005 FY | 1.89 Billion USD | 75.58% |
2005 Q1 | 1.98 Billion USD | 4.64% |
2005 Q3 | 1.88 Billion USD | -0.41% |
2005 Q4 | 1.96 Billion USD | 4.54% |
2004 FY | 1.07 Billion USD | 0.0% |
2004 Q2 | 1.07 Billion USD | -1.28% |
2004 Q1 | 1.09 Billion USD | -0.37% |
2004 Q4 | 1.89 Billion USD | 77.1% |
2004 Q3 | 1.07 Billion USD | -0.65% |
2003 Q4 | 1.09 Billion USD | 96.24% |
2003 Q1 | 583 Million USD | -6.72% |
2003 Q2 | 561 Million USD | -3.77% |
2003 Q3 | 558 Million USD | -0.53% |
2002 Q3 | 909.96 Million USD | 0.0% |
2002 FY | 561 Million USD | 0.0% |
2002 Q4 | 625 Million USD | -31.32% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Intra-Cellular Therapies, Inc. | 16.93 Million USD | 99.647% |
PainReform Ltd. | 86 Thousand USD | 30.457% |
Alvotech | 1.07 Billion USD | 99.994% |
Collegium Pharmaceutical, Inc. | 674.28 Million USD | 99.991% |
ANI Pharmaceuticals, Inc. | 315.32 Million USD | 99.981% |
Aquestive Therapeutics, Inc. | 98.82 Million USD | 99.939% |
Journey Medical Corporation | 17.73 Million USD | 99.663% |
Dynavax Technologies Corporation | 256.91 Million USD | 99.977% |
Esperion Therapeutics, Inc. | 540.94 Million USD | 99.989% |
Bright Green Corporation | 1.85 Million USD | 96.77% |
Pacira BioSciences, Inc. | 586.04 Million USD | 99.99% |
Embecta Corp. | 1.63 Billion USD | 99.996% |
Sunshine Biopharma, Inc. | 657.7 Thousand USD | 90.907% |
Sunshine Biopharma, Inc. | 657.7 Thousand USD | 90.907% |
SCYNEXIS, Inc. | 15.08 Million USD | 99.603% |
Petros Pharmaceuticals, Inc. | 8.27 Million USD | 99.277% |
Silver Spike Investment Corp. | - USD | -Infinity% |
China SXT Pharmaceuticals, Inc. | 2.64 Million USD | 97.741% |
Alpha Teknova, Inc. | 30.45 Million USD | 99.804% |
Safety Shot Inc | 1.54 Million USD | 96.139% |
Procaps Group, S.A. | 285.93 Million USD | 99.979% |
Cosmos Health Inc. | 12.42 Million USD | 99.519% |
Theratechnologies Inc. | 58.96 Million USD | 99.899% |
Harrow Health, Inc. | 190.5 Million USD | 99.969% |
Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | 90.163% |
Biofrontera Inc. | 5.39 Million USD | 98.892% |
DURECT Corporation | 20.74 Million USD | 99.712% |
Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 99.856% |
Cronos Group Inc. | 2.53 Million USD | 97.645% |
OptiNose, Inc. | 131.74 Million USD | 99.955% |
Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 99.992% |
Kala Pharmaceuticals, Inc. | 36.32 Million USD | 99.835% |
RedHill Biopharma Ltd. | 1.17 Million USD | 94.901% |
Organogenesis Holdings Inc. | 119.35 Million USD | 99.95% |
Guardion Health Sciences, Inc. | - USD | -Infinity% |
Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 99.675% |
Radius Health, Inc. | 365.31 Million USD | 99.984% |
Universe Pharmaceuticals INC | 5.48 Million USD | 98.909% |
ProPhase Labs, Inc. | 21.38 Million USD | 99.72% |
Phibro Animal Health Corporation | 525.45 Million USD | 99.989% |
Procaps Group S.A. | 285.93 Million USD | 99.979% |
TherapeuticsMD, Inc. | 8 Million USD | 99.253% |
Viatris Inc. | 18.12 Billion USD | 100.0% |
Rockwell Medical, Inc. | 13.43 Million USD | 99.555% |
Aytu BioPharma, Inc. | 15.12 Million USD | 99.605% |
SIGA Technologies, Inc. | 1.46 Million USD | 95.915% |
Tilray Brands, Inc. | 387.31 Million USD | 99.985% |
Lifecore Biomedical, Inc. | 130.36 Million USD | 99.954% |
Shineco, Inc. | 29.65 Million USD | 99.798% |
PetIQ, Inc. | 468.3 Million USD | 99.987% |
Incannex Healthcare Limited | 373 Thousand USD | 83.966% |
Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.986% |
Alimera Sciences, Inc. | 67.39 Million USD | 99.911% |
Assertio Holdings, Inc. | 40.91 Million USD | 99.854% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | 94.501% |
Clever Leaves Holdings Inc. | 2.08 Million USD | 97.134% |
Cyclo Therapeutics, Inc. | 1.03 Million USD | 94.211% |
Avadel Pharmaceuticals plc | 35.38 Million USD | 99.831% |
Hempacco Co., Inc. | 13.72 Million USD | 99.564% |
Talphera, Inc. | - USD | -Infinity% |
Alvotech | 1.07 Billion USD | 99.994% |
Eagle Pharmaceuticals, Inc. | 62.46 Million USD | 99.904% |
Lantheus Holdings, Inc. | 616.94 Million USD | 99.99% |
Currenc Group, Inc. | 31.94 Million USD | 99.813% |
Kamada Ltd. | 8.74 Million USD | 99.316% |
Indivior PLC | 281.6 Million USD | 99.979% |
Evoke Pharma, Inc. | 5 Million USD | 98.804% |
Flora Growth Corp. | 3.67 Million USD | 98.371% |
Cyclo Therapeutics, Inc. | 1.03 Million USD | 94.211% |
Evolus, Inc. | 126.54 Million USD | 99.953% |
HUTCHMED (China) Limited | 86.13 Million USD | 99.931% |
Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 99.99% |
Akanda Corp. | 3.99 Million USD | 98.504% |